Deep biomarker expertise across metabolic pathways
- Glycemic control, lipid metabolism, and inflammation markers
- Fibrosis, liver, and bone biomarkers
- Advanced panels for complex metabolic diseases
Shaping Metabolic Disease Research with Precision and Integrated Insight
Drive confident clinical decisions with comprehensive biomarker strategies, global testing capabilities, and expert scientific partnership.
Consistency across complex metabolic trials
A shift in one biomarker doesn’t always reflect what’s happening across the broader disease biology. In diabetes, obesity, and rare metabolic disorders, that disconnect is often where development decisions get harder to make. Progress depends on evidence that holds across that complexity, not just within a single result.
We help you build that evidence by connecting biomarker, genomic, and bioanalytical data across the course of a study – so treatment response and disease biology tell a consistent story, not a partial one. That’s what turns a promising signal into a defensible answer to your next development question.
Delivering the expertise your metabolic program demands
Integrated multi-omic capabilities
- Genomics, transcriptomics, and proteomics
- Ligand-binding assays and cytokine profiling
- Flow cytometry and immune profiling
- Tissue, histopathology, and spatial biology solutions
Global, harmonized laboratory network
- Standardized workflows across international laboratories
- Scalable delivery across all clinical trial phases
- Integrated data management and reporting
Metabolic capabilities at a glance
~90
metabolic disease clinical trials
9
market authorizations
~75%
trials included specialty testing
12,600
randomized patients
Comprehensive metabolic testing capabilities
Metabolic biomarker testing
Measure key metabolic processes using a broad range of validated biomarker assays to support disease characterization and treatment monitoring, including:
- Glycemic markers (HbA1c, glucose, insulin, and C-peptide)
- Lipid metabolism markers (adiponectin, leptin, and lipoproteins)
- Inflammatory and cytokine markers
- Fibrosis and liver biomarkers for non-alcoholic fatty liver disease (NASH) and non-alcoholic steatohepatitis (NAFLD)
Genomics and transcriptomics
Explore genetic and transcriptional drivers of metabolic disease to support biomarker discovery and patient stratification through:
- Next-generation sequencing (NGS), qPCR, and ddPCR
- MicroRNA and gene expression profiling
- Genetic risk markers, e.g., PNPLA3 and TM6SF2
Cell and immune profiling
Characterize immune involvement in metabolic disease through detailed cellular and functional analysis, including:
- Flow cytometry and immunophenotyping
- Cytokine profiling and functional immune assays
- PBMC and BMMC processing
Advanced bioanalytical and immunoassays
Generate high-sensitivity quantitative data across metabolic pathways using robust ligand-binding assays and multiplex immunoassay platforms, including:
- Ligand-binding assays (ELISA, MSD, and ELLA) for targeted biomarker quantification
- Multiplex cytokine panels for pathway-level analysis
- 50+ ready-to-use biomarkers across ELISA and MSD platforms
- Additional dormant assays available for rapid activation
Tissue and histopathology (NASH expertise)
Assess tissue-level changes and disease progression using standardized histopathology and advanced imaging approaches, including:
- Liver biopsy processing and scoring
- Fibrosis and steatosis assessment
- Digital pathology and AI-assisted image analysis
- Validated staining and immunohistochemistry (IHC) workflows
Global laboratory network supporting metabolic disease programs
Our globally connected laboratory network delivers consistent, high‑quality data across your clinical programs through harmonized processes and shared quality standards.
Laboratories supporting immunoassays, histopathology, and broader bioanalytical capabilities include:
- France (Paris)
- Belgium
- Netherlands
- United States (New York)
- Canada
- South Africa
- China (Shanghai)
